HEIDELBERG PHARMA AG
DGAP-News: Heidelberg Pharma AG
/ Key word(s): Patent
PRESS RELEASE Heidelberg Pharma AG: European Patent Office Grants Patent for Amatoxin Conjugates for Tumor Therapy - The grant of the patent strengthens the proprietary ATAC technology Ladenburg, Germany, 31 March 2020 - Heidelberg Pharma AG (FSE: WL6) announced today that an important patent for its own ADC technology for the manufacture of Antibody Amanitin Conjugates was granted from the European patent office. The patent is based on a patent application and named "Amatoxin armed therapeutic cell surface binding components designed for tumor therapy". The application was submitted by Professor Heinz Faulstich and employees of the German Cancer Research Centre (DKFZ). Heidelberg Pharma exclusively in-licensed the patent in December 2009. The subject matter of the patent is the crosslinking of certain carrier molecules, e.g. antibodies, via specific binding sites to amatoxins. Amatoxins are natural poisons occurring in, for example, the death cap mushroom (Amanita phalloides). To the Company's knowledge, Heidelberg Pharma is the first company worldwide to work with the corresponding toxin Amanitin to develop Antibody Targeted Amanitin Conjugates (ATACs) for the use in cancer therapy. Amanitin is known in oncology for its unique mode of action: the inhibition of RNA polymerase II, which leads the cells to programmed cell death (apoptosis) independent from cell division. This offers the opportunity to treat therapy-resistant tumors and kill quiescent tumor cells, which could result in significant clinical progress. The chemical linkage to natural Amanitin is only possible at certain positions without loss of efficacy of the molecule. The granted European patent protects the use of certain positions for the ATAC technology which are chemically easy to access, and which maintain the biologic function of the Amanitin. Prof Andreas Pahl, Chief Scientific Officer of Heidelberg Pharma AG, comments: "We are delighted that, following the US patent, also the European patent has been granted to protect certain binding sites at our toxin Amanitin. Since these binding sites at Amanitin are protected independently of the structures linked to them, these patents offer strong protection of the natural substance Amanitin for use in ADC technology and protect our unique ATAC technology." About Heidelberg Pharma's proprietary ATAC technology About Heidelberg Pharma
This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.
31.03.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | Heidelberg Pharma AG |
| Schriesheimer Str. 101 | |
| 68526 Ladenburg | |
| Germany | |
| Phone: | +49 (0)89 41 31 38 - 0 |
| Fax: | +49 (0)89 41 31 38 - 99 |
| E-mail: | investors@hdpharma.com |
| Internet: | www.heidelberg-pharma.com |
| ISIN: | DE000A11QVV0 |
| WKN: | A11QVV |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1011277 |
| End of News | DGAP News Service |
1011277 31.03.2020
